AllianceRx Walgreens chosen as exclusive distributor of Vivjoa
Specialty pharmacy patients now have exclusive access to VIVJOA through AllianceRx Walgreens Pharmacy. VIVJOA (oteseconazole), manufactured by Mycovia Pharmaceuticals, Inc.
CDR
Retailing accounts for most private sector jobs
WASHINGTON – The retail industry continues to be a top employer, according to a new report released by the National Retail Federation on Monday, which found that retailers supported 55 million full-time and part-time jobs in 2022, accounting for 26% of total U.S. employment.
CRN challenges constitutionality of New York law
The Council for Responsible Nutrition (CRN), the leading trade association for the dietary supplement and functional food industry, today announced the filing of a lawsuit challenging the constitutionality of a recently enacted New York law that would restrict consumer access to safe and beneficial
Bast rejoins Greater Than One as chief strategy officer
Andrew Bast will be rejoining Media marketing and technology agency Greater Than One as chief strategy officer. Bast brings the art and science of strategic planning to forge dynamic, insight-driven strategies which resonate deeply with clients’ customers, the agency says.
Former Eckerd CEO Stew Turley dies at 89
Stew Turley, who guided the evolution of Eckerd Corp. for three decades, died last week at his home in Florida after a battle with lymphoma. He was 89. During the course of his tenure at the retailer, which began in 1966 when he was named manager of non-drug operations, Eckerd grew to 2,778
Valdez is COO of Greater Than One
Jason Valdez has been promoted to chief operating officer of Greater Than One, a media marketing and technology agency focused on healthcare. He is responsible for overall operations and ensuring the agency’s mission of building better healthcare experiences for customers.
Loblaw to invest over $2 billion to open more than 40 additional stores
BRAMPTON, ON – Loblaw Cos., Canada’s food and pharmacy retail leader, expects to invest more than $2 billion dollars into the Canadian economy in 2024.
Cepham introduces Senolytics inspired by Ayurveda and TCM for sustainable aging
Cepham, a leader in Ayurvedic nutraceuticals research and sustainable self-care solutions, has announced the expansion of its Sustainable Aging product line to include senolytics, aimed at redefining approaches to healthy aging.
CVS beats Q4 sales and earnings projections
CVS Health topped analysts’ forecasts for fourth quarter sales and profits, but cut its full year earnings outlook, citing rising medical costs that are hurting the insurance industry. Revenue for the three months ended December 31 climbed 11.9% from the year-ago period to $93.
Discount Drug Mart adds self-service registration kiosk
Discount Drug Mart, the regional chain that “Saves you the Run Around,” is now saving time on vehicle registration renewals.
WBA beats Q1 projections, cuts dividend
Walgreens Boots Alliance topped Wall Street’s expectations for first quarter sales and earnings, but slashed its quarterly dividend nearly in half. WBA cut its dividend to 25 cents per share from 48 cents per share, reducing the payout for the first time in nearly five decades.
NACDS praises House passage of bipartisan bill to help deliver essential PBM reforms in Medicaid
NACDS is applauding the passage of the Lower Costs, More Transparency Act (H.R. 5378) by the U.S. House of Representatives today. The bill — which was introduced by U.S. Representative Cathy McMorris Rodgers (R-WA) on September 8 — is a vital aspect of pharmacy benefit manager (PBM) reform.
Dr. Reddy’s partners with Coya to develop ALS treatment
Dr. Reddy’s Laboratories is collaborating with Coya Therapeutics Inc. to develop and commercialize an investigational combination therapy for the treatment of amyotrophic lateral sclerosis (ALS). Coya has granted Dr.
Lilly’s Omvoh now available in the U.S. for ulcerative colitis
The Food and Drug Administration has approved Eli Lilly and Co.’s Omvoh (mirikizumab-mrkz) infusion (300 mg/15 mL)/injection (100 mg/mL), as the first and only interleukin-23p19 (IL-23p19) antagonist for the treatment of moderately to severely active ulcerative colitis (UC) in adults.
CVS’ Q3 sales and profits beat forecasts
CVS Health topped Wall Street’s estimates for third quarter revenue and earnings. Adjusted earnings per share of $2.21 exceeded analysts’ predicted $2.13, while revenue of $89.76 billion beat the forecast of $88.2 billion.